PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Total liabilities 2022–2025
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) total liabilities at each fiscal year-end, per SEC filings.
$7.0MFY2025 · since FY2022: $8.3M → $7.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.0M | +0.4% |
| FY2024 | $7.0M | -22.9% |
| FY2023 | $9.0M | +9.4% |
| FY2022 | $8.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PVCT financial trends
PVCT RevenuePVCT Net incomePVCT Net marginPVCT Gross profitPVCT Gross marginPVCT Operating incomePVCT Operating marginPVCT Operating cash flowPVCT Free cash flowPVCT Capital expendituresPVCT Return on equityPVCT Stock buybacksPVCT Dividends paidPVCT Total assetsPVCT Shareholders’ equityPVCT overview →